The effect of plasma exchange on serum anti-JC virus antibodies

Multiple Sclerosis Journal

Volumn 19, Issue 7, 2013, Pages 912-919

  Subramanyam, Meena ^a   Plavina, Tatiana ^a   Khatri, Bhupendra O ^b   Fox, Robert J ^c   Goelz, Susan E ^d  

^a BIOGEN   (United States)

^b Aurora St Luke's Center for Neurological Disorders Regional Multiple Sclerosis Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ELAN PHARMACEUTICALS   (United States)

Author keywords

anti JCV antibodies; immune reconstitution; multiple sclerosis; natalizumab; Plasma exchange; progressive multifocal leukoencephalopathy

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; JC VIRUS; LIMIT OF DETECTION; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;

EID: 84878350126     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512467502     Document Type: Article

References (17)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
2. Biogen Idec Inc. Tysabri (natalizumab) injection. Full prescribing information. http://www.tysabri.com/en-US/tysb/site/pdfs/TYSABRI-pi.pdf (accessed 27 January 2012).
3. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 911-923
5. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005 ; 353: 1912-1925
6. Brew BJ, Davies NWS, Cinque P, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010 ; 6: 667-679
7. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010 ; 61: 35-47
8. Sunyaev SR, Lugovskoy A, Simon K, et al. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009 ; 5: e1000368
9. Tan CS, Koralnik IJ. Beyond progressive multifocal leukoencephalopathy: Expanded pathogenesis of JC virus infection in the central nervous system. Lancet Neurol. 2010 ; 9: 425-437
10. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 ; 72: 402-409
11. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol. 68: 295-303
12. Weinshenker BG, O'Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999 ; 46: 878-886
13. Biogen Idec Inc. Medical information. https://medinfo.biogenidec.com/ medinfo (accessed 26 September 2012).
14. Bloomgren G, Richman S, Hoterman C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012 ; 366: 1870-1880
15. Ryschkewitsch CF, Jensen PN, Monaco MC, et al. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2010 ; 68: 384-391
16. Goelz SE, Gorelik L, Subramanyam M. Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol. 2011 ; 69: 429-430
17. Cortese I, Chaudhry V, So YT, et al. Evidence-based guideline update: Plasmapheresis in neurologic disorders. Neurology. 2011 ; 76: 294-300